• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index

    12/23/24 9:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care
    Get the next $FMS alert in real time by email
    • Ranking puts Fresenius Medical Care among the best-in-class sustainability performers in the world and Europe
    • The company recorded progress towards its sustainability targets
    • Sustainability is one of the essential drivers for future

    BAD HOMBURG, Germany, Dec. 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has been recognized as a sustainability leader with the inclusion in the Dow Jones Sustainability World Index and with the inclusion in the Dow Jones Sustainability Europe Index for the 15th time. Dow Jones Sustainability Index (DJSI) is one of the world's leading ESG (Environmental, Social, Governance) stock indices.

    Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index

    Helen Giza, CEO of Fresenius Medical Care AG, said: "We believe that sustainability and excellent patient care are inextricably linked. I am very proud that our employees' commitment to our sustainability efforts has been recognized through the inclusion in the indices. Considering sustainability in our products and the way we work helps to ensure that we provide excellent, high-quality services for future generations."

    Fresenius Medical Care continuously incorporates sustainability into its global business operations. The company's approach centers on three strategic focus areas:

    • Enhancing quality of care and access to healthcare,
    • building the best teams to serve patients, and
    • reducing the company's environmental footprint.

    In 2023, FME has reported progress toward its sustainability targets and governance:

    • Fresenius Medical Care improved its Net Promoter Score to 72, reflecting a high patient satisfaction with its services.
    • The company increased the share of women in the top two management levels below Management Board to 34%, underlining its commitment to diversity, equity and inclusion.
    • FME moved ahead with its climate neutrality action plan, with Scope 1 and 2 emissions in 2023 decreasing by 16% from a 2020 baseline. The reduction of CO2e emissions is included in the targets for the long-term compensation of the Management Board members for 2024.
    • In 2024 the company signed five virtual power purchase agreements for approximately 580 gigawatt hours per year with wind and solar farms in Germany and the U.S. It also submitted the commitment letter to the Science Based Target initiative (SBTi).

    The Dow Jones Sustainability Indices are the longest-running global sustainability benchmarks. Each year, over 13,000 companies are invited to participate in the Corporate Sustainability Assessment (CSA). Approximately 3,500 of the largest companies worldwide are eligible for inclusion in any DJSI. The annual review evaluates companies' sustainability performance in areas relevant to each industry.

    An overview of Fresenius Medical Care's progress in sustainability can be found in the company's non-financial group report here.

    About Fresenius Medical Care:

    Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,732 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 308,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

    For more information visit the company's website at www.freseniusmedicalcare.com.

    Disclaimer:

    This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

    Media contact

    Christine Peters

    T +49 160 60 66 770

    [email protected]

    Contact for analysts and investors

    Dr. Dominik Heger

    T +49 6172 609 2601

    [email protected]

    www.freseniusmedicalcare.com

    Fresenius Medical Care starts the year with strong earnings growth (PRNewsfoto/Fresenius Medical Care North Am)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-listed-in-the-dow-jones-sustainability-world-index-and-for-the-15th-time-in-the-dow-jones-sustainability-europe-index-302338375.html

    SOURCE Fresenius Medical Care Holdings, Inc.

    Get the next $FMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FMS

    DatePrice TargetRatingAnalyst
    1/20/2026Buy → Neutral
    Goldman
    10/15/2025Neutral → Underperform
    BofA Securities
    9/2/2025Neutral → Sell
    UBS
    12/2/2024Underperform → Neutral
    BofA Securities
    11/6/2024$25.60Buy
    Berenberg
    1/8/2024Equal-Weight → Underweight
    Morgan Stanley
    11/24/2023Reduce → Hold
    HSBC Securities
    11/17/2023Hold → Buy
    Societe Generale
    More analyst ratings

    $FMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fresenius Medical downgraded by Goldman

    Goldman downgraded Fresenius Medical from Buy to Neutral

    1/20/26 9:08:47 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical downgraded by BofA Securities

    BofA Securities downgraded Fresenius Medical from Neutral to Underperform

    10/15/25 8:35:43 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical downgraded by UBS

    UBS downgraded Fresenius Medical from Neutral to Sell

    9/2/25 8:32:54 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Fresenius Medical Care AG

    3 - Fresenius Medical Care AG (0001333141) (Issuer)

    3/18/26 10:01:24 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    SEC Filings

    View All

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    4/14/26 6:00:30 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    2/24/26 2:56:17 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form IRANNOTICE filed by Fresenius Medical Care AG

    IRANNOTICE - Fresenius Medical Care AG (0001333141) (Filer)

    2/24/26 12:59:30 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

    Strong organic revenue growth1 in 2025 of 8% driven by all operating segmentsDriven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3%Reported operating income grew by 31%, reported net income3 by 82%Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback programDividend of EUR 1.49 (+3%) planned to be proposedFY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwindsBAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains.

    2/24/26 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

    The second tranche of the share buyback is expected to be executed by May 8, 2026The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, significantly earlier than originally plannedBAD HOMBURG, Germany, Jan. 9, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion. Under the second tranche, the company plans to repurchase its own shares for a t

    1/9/26 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

    Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical OfficerAs part of a planned transition Franklin W. Maddux will retire by year endBAD HOMBURG, Germany, Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026. Mr. Hugh-Jones will serve as Global Chief Medical Officer. Mr. Hugh-Jones will succeed Franklin (F

    12/10/25 8:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Leadership Updates

    Live Leadership Updates

    View All

    Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

    Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical OfficerAs part of a planned transition Franklin W. Maddux will retire by year endBAD HOMBURG, Germany, Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026. Mr. Hugh-Jones will serve as Global Chief Medical Officer. Mr. Hugh-Jones will succeed Franklin (F

    12/10/25 8:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement

    Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care EnablementAs part of a planned transition Dr. Katarzyna Mazur-Hofsäß will retire by year endBAD HOMBURG, Germany, Oct. 1, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, has appointed Joseph E. (Joe) Turk (57) as a member of the Management Board, effective January 1, 2026. Mr. Turk will serve as Chief Executive Officer of the global operating segment Care Enablement.

    10/1/25 9:35:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment

    Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician investors in Interwell Health (IWH), accelerating the timeline originally set during the merger of Cricket Health, IWH, and Fresenius Health Partners when it was completed in August 2022Tommy P. O'Connor appointed CEO of Interwell Health and Operating Segment leader of Value-Based Care to enhance benefits of the vertical integration and accelerate value creation in line with the FME Reignite strategyBAD HOMBURG, Germany, Sept. 18, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, to

    9/18/25 3:30:00 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Financials

    Live finance-specific insights

    View All

    Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

    Strong organic revenue growth1 in 2025 of 8% driven by all operating segmentsDriven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3%Reported operating income grew by 31%, reported net income3 by 82%Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback programDividend of EUR 1.49 (+3%) planned to be proposedFY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwindsBAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains.

    2/24/26 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025

    Strong organic revenue growth1 of 10% driven by all operating segmentsPositive U.S. same market treatment growth of 0.1 % in line with expectationsAccelerated operating income2 growth of 28% at constant currency, leading to a step-change in margin expansion to 11.7%Reported operating income grew by 3%, reported net income3 by 29%Net leverage ratio further improved to 2.6x, in parallel to share buyback and Value-Based Care investmentsFY 2025 outlook confirmedBAD HOMBURG, Germany, Nov. 4, 2025 /PRNewswire/ -- "In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income2 growth increased as planned for the third consecutive quarter, underlin

    11/4/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025

    Strong organic revenue growth1 of 7% driven by all operating segmentsStable U.S. same market treatment development driven by accelerating patient inflowFME25+ savings of EUR 58 million contributed to earningsOperating income2 grew by 13% at constant currency, further driving margin expansionStable reported operating income and 20% increase in reported net income3Operating cash flow improved strongly by 75%, net leverage ratio improved to 2.7xFY 2025 outlook confirmedFirst tranche of announced share buyback to be initiated in AugustBAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth

    8/5/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fresenius Medical Care AG

    SC 13G - Fresenius Medical Care AG (0001333141) (Subject)

    11/14/24 4:08:53 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Fresenius Medical Care AG (Amendment)

    SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)

    2/13/24 1:36:58 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Fresenius Medical Care AG (Amendment)

    SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)

    12/7/23 11:45:52 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care